Pharma 5.0 Global Market Opportunities and Strategies to 2035

This report describes and explains the pharma 5 market and covers 2020-2025, termed the historic period, and 2025-2030, 2035F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.

The global pharma 5 market reached a value of nearly $78.3 billion in 2025. The market is expected to grow from $78.3 billion in 2025 to $381.13 billion in 2030 at a rate of 37.2%. The market is then expected to grow at a CAGR of 35.3% from 2030 and reach $1.72 trillion in 2035.

Growth in the historic period resulted from rising adoption of personalized medicine, expansion of real-world evidence (RWE) and real-world data (RWD) in clinical decisions, rising investments in advanced therapeutic modalities and rising focus on patient-centric care models. Factors that negatively affected growth in the historic period were high capital investment requirements and high rate of clinical trial failures.

Going forward, adoption of human-machine collaborative automation in pharmaceutical, growing focus on sustainable and cost-efficient drug development, increasing burden of chronic diseases and rising investments in big data analytics and cloud computing in healthcare will drive growth. Factors that could hinder the growth of the pharma 5 market in the future include regulatory uncertainty and uneven global acceptance, unclear return on investment (ROI) and impact of trade war and tariff.

The pharma 5 market is segmented by type into personalized medicine platforms, digital therapeutics, artificial intelligence-driven drug discovery, smart manufacturing and artificial intelligence-based diagnostics. The artificial intelligence-driven drug discovery market was the largest segment of the pharma 5 market segmented by type, accounting for 32.7% or $25.61 billion of the total in 2025. Going forward, the artificial intelligence-driven drug discovery segment is expected to be the fastest growing segment in the pharma 5 market segmented by type, at a CAGR of 40.4% during 2025-2030.

The pharma 5 market is segmented by technology into cloud computing, artificial intelligence (AI), machine learning (ML), internet of things (IoT) and robotic process automation (RPA). The artificial intelligence (AI) market was the largest segment of the pharma 5 market segmented by technology, accounting for 30.3% or $23.71 billion of the total in 2025. Going forward, the artificial intelligence (AI) segment is expected to be the fastest growing segment in the pharma 5 market segmented by technology, at a CAGR of 41.7% during 2025-2030.

The pharma 5 market is segmented by therapeutic area into cardiovascular diseases, oncology, infectious diseases, neurology and other therapeutic areas. The cardiovascular diseases market was the largest segment of the pharma 5 market segmented by therapeutic area, accounting for 33.1% or $25.95 billion of the total in 2025. Going forward, the oncology segment is expected to be the fastest growing segment in the pharma 5 market segmented by therapeutic area, at a CAGR of 53.2% during 2025-2030.

The pharma 5 market is segmented by end-user into pharmaceutical and biotech companies, healthcare providers, contract research organizations (CROs) and research institutes. The pharmaceutical and biotech companies market was the largest segment of the pharma 5 market segmented by end-user, accounting for 49.7% or $38.91 billion of the total in 2025. Going forward, the contract research organizations (CROs) segment is expected to be the fastest growing segment in the pharma 5 market segmented by end-user, at a CAGR of 46.4% during 2025-2030.

The pharma 5 market is segmented by deployment mode into on-premises and cloud-based. The on-premises market was the largest segment of the pharma 5 market segmented by deployment mode, accounting for 74.7% or $58.48 billion of the total in 2025. Going forward, the cloud-based segment is expected to be the fastest growing segment in the pharma 5 market segmented by deployment mode, at a CAGR of 44.2% during 2025-2030.

North America was the largest region in the pharma 5 market, accounting for 54.5% or $42.67 billion of the total in 2025. It was followed by Western Europe, Asia Pacific and then the other regions. Going forward, the fastest-growing regions in the pharma 5 market will be Asia Pacific and Eastern Europe where growth will be at CAGRs of 79.9% and 55.6% respectively. These will be followed by Western Europe and North America where the markets are expected to grow at CAGRs of 31.6% and 30.5% respectively.

Market-trend-based strategies for the pharma 5 market include emergence of AI-powered medical content hubs to transform commercialization, emergence of automated comparative outcomes platforms to strengthen evidence-driven decision-making and emergence of predictive development platforms to advance pharma 5 operations.

The global pharma 5 market is fairly concentrated, with large players operating in the market. The top 10 competitors in the market made up 42.492% of the total market in 2024. Pfizer Incorporated was the largest competitor with a 6.347% share of the market, followed by AstraZeneca Plc with 5.884%, Roche Holding AG with 5.305%, Johnson & Johnson, with 5.166%, Novartis AG, with 4.380%, Eli Lilly and Company with 3.513%, Sanofi S.A. with 3.225%, Bristol Myers Squibb Company with 3.224%, GSK plc with 2.919% and Novo Nordisk with 2.528%.

The top opportunities in the pharma 5 market segmented by type will arise in the artificial intelligence-driven drug discovery segment, which will gain $114.03 billion of global annual sales by 2030. The top opportunities in the pharma 5 market segmented by deployment mode will arise in the on-premises segment, which will gain $198.9 billion of global annual sales by 2030. The top opportunities in the pharma 5 market segmented by technology will arise in the artificial intelligence (AI) segment, which will gain $111.76 billion of global annual sales by 2030. The top opportunities in the pharma 5 market segmented by therapeutic area will arise in the oncology segment, which will gain $162.31 billion of global annual sales by 2030. The top opportunities in the pharma 5 market segmented by end-user will arise in the pharmaceutical and biotech companies segment, which will gain $156.74 billion of global annual sales by 2030. The pharma 5 market size will gain the most in the USA at $108.55 billion.

Player-adopted strategies in the pharma 5 market include focus on enhancing operational capabilities through strategic partnerships, new developments and strategic investments.

To take advantage of the opportunities, the analyst recommends the pharma 5 companies to focus on AI-driven platforms to enhance evidence generation and content delivery, focus on automated comparative outcomes platforms for evidence-based decisions, focus on predictive development platforms to improve drug development efficiency, focus on artificial intelligence-driven drug discovery to capture market leadership, focus on artificial intelligence to lead pharma 5 innovation, focus on cloud-based platforms to accelerate pharma 5 operations, focus on oncology to capture fastest-growing pharma 5 opportunities, focus on contract research organizations to accelerate pharma 5 growth, expand in emerging markets, continue to focus on developed markets, focus on expanding cloud-based and on-premises distribution channels, focus on value-based and tiered pricing strategies, focus on digital-first and data-driven promotion, focus on collaborative and educational promotion and focus on engaging key end-users directly.

This product will be delivered within 3-5 business days.